Electrochemotherapy in the Treatment of Melanoma Skin Metastases: A Report on 31 Cases

Mir-Bonafé, José M; Vilalta, A.; Alarcón, Ivette; Carrera, Cristina; Puig, Susana; Malvehy, Josep; Rull, R.; Bennàssar, Antoni

doi:10.1016/j.adengl.2015.03.004

Cited by 13 publications

(23 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six of them were excluded from the final analysis for the following reasons: one letter to editor, one case report, one with no data on tumor response, one without separated data on ECT, one reporting on the same patients population of a more recent study by the same authors, and one reporting on primary MM. Seven studies had a retrospective design [16][17][18][19][20][21][22], ten were prospective [11,12,[23][24][25][26][27][28][29][30] and one was a retrospective-prospective analysis [31]. Six studies were published before ESOPE guidelines were issued in 2006 [16-18, 23, 24, 26].…”

Section: Resultsmentioning

confidence: 99%

“…Most lesions were in the trunk and extremities. The size of the treated metastases was reported heterogeneously: some authors reported the volume [11,16,23,24], others the diameter [12,18,19,21,[25][26][27][28][29][30], while four papers did not describe this data [17,20,22,31]. Looking at the diameter, the range was 2-260 mm.…”

Section: Patients and Tumors Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Electrochemotherapy of skin metastases from malignant melanoma: a PRISMA-compliant systematic review

Ferioli

Lancellotta

Perrone³

et al. 2022

Clin Exp Metastasis

View full text Add to dashboard Cite

The main treatment of MM metastases are systemic therapies, surgery, limb perfusion, and intralesional talimogene laherparepvec. Electrochemotherapy (ECT) is potentially useful also due to the high response rates recorded in cancers of any histology. No randomized studies comparing ECT with other local therapies have been published on this topic. We analyzed the available evidence on efficacy and toxicity of ECT in this setting. PubMed, Scopus, and Cochrane databases were screened for paper about ECT on MM skin metastases. Data about tumor response, mainly in terms of overall response rate (ORR), toxicity (both for ECT alone and in combination with systemic treatments), local control (LC), and overall survival (OS) were collected. The methodological quality was assessed using a 20-item validated quality appraisal tool for case series. Overall, 18 studies were included in our analysis. In studies reporting “per patient” tumor response the pooled complete response (CR) was 35.7% (95%CI 26.0–46.0%), and the pooled ORR was 80.6% (95%CI 68.7–90.1%). Regarding “per lesion” response, the pooled CR was 53.5% (95%CI 42.1–64.7%) and the pooled ORR was 77.0% (95%CI 56.0–92.6%). One-year LC rate was 80%, and 1-year OS was 67–86.2%. Pain (24.2–92.0%) and erythema (16.6–42.0%) were the most frequent toxicities. Two studies reported 29.2% and 41.6% incidence of necrosis. ECT is effective in terms of tumor response and tolerated in patients with skin metastases from MM, albeit with a wide variability of reported results. Therefore, prospective trials in this setting are warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Patients and Tumors Characteristicsmentioning

confidence: 99%

Electrochemotherapy of skin metastases from malignant melanoma: a PRISMA-compliant systematic review

Ferioli

Lancellotta

Perrone³

et al. 2022

Clin Exp Metastasis

View full text Add to dashboard Cite

show abstract

“…The adverse effects of electrochemotherapy seem to be mild and transient. In most of the studies, complications such as erythema, oedema, and pain appeared immediately and resolved after a few days [108]. Late side effects and systemic toxicity were also mild due to low chemotherapy drug doses [108].…”

Section: Discussionmentioning

confidence: 99%

“…In most of the studies, complications such as erythema, oedema, and pain appeared immediately and resolved after a few days [108]. Late side effects and systemic toxicity were also mild due to low chemotherapy drug doses [108]. Post-procedure pain seems to be associated with moderate or severe pain before treatment, size of the largest treated lesion, previous irradiation, and a high level of current [15,22,85,101].…”

Section: Discussionmentioning

confidence: 99%

Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis

Jafari¹,

Lak²,

Gazdhar³

et al. 2018

European Journal of Dermatology

View full text Add to dashboard Cite

Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis Electrochemotherapy is becoming a promising technique for the management of malignancies of skin and non-skin origin. The current review aims to clarify current knowledge on administration of electrochemotherapy for the treatment of various skin tumours. A systematic literature search was performed, up to the end of 2016, on studies in which the application of electrochemotherapy for management of primary and metastatic cutaneous malignant tumours was assessed. Having selected appropriate studies, pooled estimates of mean objective (complete) responses, with 95% confidence intervals (CIs), were calculated to assess treatment efficacy. Finally, the main emerging themes from the papers were discussed in more detail. From 465 records identified through database searching, a total of 128 studies were screened, of which 70 were included for review. After a pooled analysis, the estimate for mean objective response following electrochemotherapy was 84.02% (95% CI: 80.08-87.61). Furthermore, the pooled estimate of objective treatment response of evaluated studies was 83.91% (95% CI: 79.15-88.17%) for bleomycin and 80.82% (95% CI: 66.00-92.36%) for cisplatin. Electrochemotherapy is a feasible, inexpensive, fast and easy technique to perform local treatment, regardless of tumour type, with a low level of adverse effects and patient discomfort. This method can be applied alone for patients with primary cutaneous lesions, or local or locoregional metastases, or as an additional treatment modality in patients with distant metastases.

show abstract

“…Electroporation (EP) or the drugs on their own do not influence the growth of tumors, but the combination of the EP and bleomycin has potent antitumor effects. In previous reports, ECT has shown to be effective as palliative treatment of cutaneous and subcutaneous metastases in patients with cutaneous melanoma [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28].…”

Section: Discussionmentioning

confidence: 99%

Electrochemotherapy in Melanoma Patients: A Single Institution Experience

et al. 2015

View full text Add to dashboard Cite

show abstract

Electrochemotherapy in the Treatment of Melanoma Skin Metastases: A Report on 31 Cases

Abstract: Electrochemotherapy is a very effective, safe, and efficient treatment for advanced locoregional disease in patients with unresectable melanoma lesions.

Cited by 13 publications

References 34 publications

Electrochemotherapy of skin metastases from malignant melanoma: a PRISMA-compliant systematic review

Electrochemotherapy of skin metastases from malignant melanoma: a PRISMA-compliant systematic review

Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis

Electrochemotherapy in Melanoma Patients: A Single Institution Experience

Contact Info

Product

Resources

About